Work

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps2652

Authors: Timothy A Yap, Kyriakos P. Papadopoulos, Patricia LoRusso, Deborah J.L. Wong, Siwen Hu-Lieskovan, Josefin-Beate Holz, FS118-17101 Study Team

Institutions: The University of Texas MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, Yale Cancer Center, Yale University, University of California, Los Angeles, F-star (United Kingdom)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947847546

Cites:

Cited by: 9

Related to: 10